progressive pulmonary fibrosis
Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis
This is the first treatment breakthrough in pulmonary fibrosis in over a decade
Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim
The collaboration began in 2013 and was later expanded in 2020 and 2023
Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases
The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline
PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis
Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m
The deal focuses on T cell-based therapies for autoimmune disease
Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients
Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year
LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront
Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis
Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis
The rare form of psoriasis can lead to serious complications such as sepsis and heart failure
Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials
The candidate is currently under review for both interstitial lung diseases in the EU and US
Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m
The companies will focus on developing treatments for hard-to-treat ALT-positive tumours
Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m
The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys